Intra-Cellular Therapies to Host Second Quarter 2015 Financial Results Conference Call and Webcast

NEW YORK, July 30, 2015 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:00 a.m. Eastern Time on Wednesday, August 5, 2015, to discuss financial results for the second quarter ended June 30, 2015, and provide a business update.

To access the live conference call via phone, dial 1-844-835-6563. International callers may access the live call by dialing 1-970-315-3916. The conference ID number for the live call is 94982004.

The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software. The webcast replay will be available on the website until August 12, 2015.

About Intra-Cellular Therapies

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.

CONTACT: Juan Sanchez, M.D.
         Vice President
         Corporate Communications
         and Investor Relations of Intra-Cellular Therapies, Inc.
         Phone:  212-923-3344

         Burns McClellan, Inc.
         Lisa Burns/Carol Werther (Investors)
         Justin Jackson (Media)
         [email protected]
         212-213-0006

Source: Intra-Cellular Therapies, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Intra-Cellular Therapies (ITCI) PT Raised to $103 at Baird
• Liberty Oilfield Services (LBRT) Misses Q1 EPS by 6c, provides outlook
• Equifax (EFX) shares tumble as Q2, full-year guidance falls short